FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2
  • Home
  • About
  • Projects
    • P1 Lymph-Transplant
    • P2 Modulators of LA
    • N1 Ocular GvHD
    • N2 ABCB5 & Pterygium
    • P4 Ocular Melanoma
    • P5 Myeloid Cells
    • P6 Microglia in AMD
    • P8 Uveitis
    • C1 Eye Imaging
    • C2 Management
  • Team
    • Executive Board
    • Research Groups
    • Central Projects
    • Associated projects
    • Alumni
  • Publications
  • Links
  • Events
    • Guest lectures
    • Retreats
    • Symposium
  • News
✕

ARREST BLINDNESS

Members and guests of the COST action meeting at EURCORNEA 2015 in Barcelona

Members and guests of the COST action meeting at EURCORNEA 2015 in Barcelona

ARREST BLINDNESS

Department of Ophthalmology successful in Horizon 2020 application: ARREST BLINDNESS funded with 6 Million Euros

The successful Horizon 2020 project addresses corneal blindness, which is the second largest cause of blindness globally, and is also the topic of two FOR 2240 projects (P1, P5). The four-year project is called Advanced Regenerative and RESTtorative Therapies to combat corneal BLINDNESS (ARREST BLINDNESS). The objective of ARREST BLINDNESS is to develop new regenerative-based therapies for the cornea, addressing the translation of regenerative medicine, bio-artificial organs, tissue-engineered scaffolds, and advanced cell and molecular therapies into clinical use. This program will help to alleviate the worldwide problem of corneal blindness. ARREST BLINDNESS is a consortium of 14 partners across 8 European countries including 5 companies, comprising some of the leading academic centers for corneal regeneration research in Europe. The consortium is led by Neil Lagali (Linköping, Sweden), and includes (amongst others) Claus Cursiefen (Cologne, Germany), Nadia Zakaria (Antwerp, Belgium), Juana Gallar (Alicante, Spain), Isabel Dapena (Rotterdam, The Netherlands), Jesper Hjortdal (Aarhus, Denmark) and Martine Jager (Leiden, The Netherlands). ARREST BLINDNESS builds on the recently funded 4 year EU COST Action (BM1302: JOINING FORCES IN CORNEAL REGENERATION; www.biocornea.eu) which aims to develop an artificial biocornea and has helped to form a paneuropean network of corneal regeneration researchers. This is led by Prof. Cursiefen from Cologne and Prof. Jager from Leiden and includes cornea researchers from most European countries. Also several members of FOR 2240 (Deniz Hos, Felix Bock, Claus Cursiefen) are members of COST Action BM1302. The Cologne part in ARREST BLINDNESS is focussed on translational studies to regenerate corneal avascularity.

Related posts

January 7, 2023

Dr. Sarah Barbara Zwingelberg, is awarded Belmonte Fellowship for research on the neurobiology of the ocular surface


Read more
December 15, 2022

Leonhard Klein-Preis for Prof. Matthaei


Read more
November 22, 2022

4th Shanghai-Cologne Scientific Symposium


Read more

News

  • Rare eye diseases: Eight million euros for research: Funding for four years
  • Dr. Sarah Barbara Zwingelberg, is awarded Belmonte Fellowship for research on the neurobiology of the ocular surface
  • Experimental Glaucoma Research Group awarded and funded
  • Leonhard Klein-Preis for Prof. Matthaei
  • 4th Shanghai-Cologne Scientific Symposium

More information

  • Publication highlights
  • Jobs
  • Contact
  • Impressum
  • Datenschutz

Newest publications

Supplemental Anti Vegf A-Therapy Prevents Rebound…(2020)


Bevacizumab Induces Upregulation of Keratin 3 and VEGFA in Human…(2020)


Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional…(2020)


Contact

Claudia Bock
Management Office
DFG Research Unit FOR2240
Department of Ophthalmology
University of Cologne
Kerpener Str. 62
50937 Cologne, Germany

www.for2240.de

Tel. +49 (0)221 478 32845
Fax. +49 (0)221 478 5094
claudia.bock@uk-koeln.de

Partnerlogos

© 2021 FOR2240 | Online Marketing von Resulted Lübeck